Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Sulindac
100%
Cyclooxygenase Inhibitors
87%
Peroxisome Proliferator-activated Receptor
62%
Indomethacin
50%
Cyclooxygenase-1 (COX-1)
50%
Desmethyl
50%
Stable Angina
50%
Angina
50%
Chronic Stable Angina
50%
Long-term Clinical Outcome
50%
Myocardial Infarction
33%
Coronary Artery Disease
33%
Coronary Collateral Circulation
33%
Rentrop Grade
33%
Gastrointestinal Toxicity
25%
Sulindac Sulfide
19%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
19%
Collateral Grade
16%
Coronary Angiography
16%
Consecutive Patients
16%
Myocardial Revascularization
16%
Peripheral Vascular Disease
16%
Revascularization
16%
Percutaneous Intervention
16%
Adverse Events
16%
Congestive Heart Failure
16%
Single Vessel
16%
Peroxisome Proliferators
14%
Response Element
14%
Adipocyte Apoptosis
12%
Intestinal Homeostasis
12%
Colon Cancer Cells
12%
Anticancer Drugs
12%
Off-target Effects
12%
Adipocyte Differentiation
12%
Antidiabetic Drug
12%
Inducer
12%
Etiology
12%
Inhibitory Activity
12%
C57BL6 Mice
12%
Benzylidene
7%
Adipocyte Fatty Acid-binding Protein (A-FABP)
7%
Scintillation Proximity Assay
7%
Oligonucleotides
7%
Optimal Activity
7%
Induced Expression
7%
Liver-type Fatty Acid-binding Protein (L-FABP)
7%
Direct Binding
7%
Carboxylic Acids
7%
Troglitazone
7%
Medicine and Dentistry
Stable Angina Pectoris
50%
Angina pectoris
50%
Stable Angina
50%
Peroxisome Proliferator Activated Receptor Gamma
50%
Sulindac
50%
Peroxisome Proliferator Activated Receptor
50%
Prostaglandin Synthase
50%
Revascularization
33%
Myocardial Infarction
33%
Coronary Artery Disease
33%
Peroxisome Proliferator Activated Receptor Gamma Agonist
25%
DNA Responsive Element
25%
Peroxisome Proliferator-Activated Receptor
25%
Carvedilol
16%
Angiography
16%
Coronary Angiography
16%
Congestive Heart Failure
16%
Percutaneous Intervention
16%
Peripheral Vascular Disease
16%
Adverse Event
16%
Fatty Acid Binding Protein 4
12%
Sulindac Sulfide
12%
Nonsteroid Antiinflammatory Agent
12%
Protein Z
12%
Oligonucleotide
12%
Luciferase
12%
Troglitazone
12%
Carboxylic Acid
12%
Pharmacology, Toxicology and Pharmaceutical Science
Sulindac
100%
Prostaglandin Synthase
100%
Peroxisome Proliferator Activated Receptor
58%
Indometacin
50%
Peroxisome Proliferator Activated Receptor Gamma
50%
Peroxisome Proliferator
25%
Peroxisome Proliferator Activated Receptor Gamma Agonist
25%
Sulindac Sulfide
20%
Non-Steroidal Anti-Inflammatory Drug
20%
Gastrointestinal Toxicity
16%
Diseases
16%
Fatty Acid Binding Protein 4
12%
Luciferase
12%
Carboxylate
12%
Fatty Acid Binding Protein
12%
Oligonucleotide
12%
EC50
12%
Troglitazone
12%
Antidiabetic Agent
8%
Anticarcinogen
8%
Colon Carcinoma
8%
Etiology
8%
Prostaglandin Synthase Inhibitor
8%